ArticleTherapeutic advances in medical oncology2026
Ablation of pulmonary oligometastasis in advanced hepatocellular carcinoma treated with Lenvatinib: a retrospective multicenter study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with hepatocellular carcinoma (HCC) and pulmonary oligometastasis (PO), the therapeutic effects of metastases ablation remain unclear. Objective: This study aimed to compare the efficacy of metastases ablation combined with Lenvatinib (Ablation + Len) with that of Lenvatinib alone (Len) in patients with HCC and PO. Design: A multicenter retrospective study. Methods: This study included 202 patients in the Len group and 182 patients in the Ablation + Len group. Propensity score matching and inverse probability treatment weighting analyses were used to balance baseline variables between the two groups. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was overall survival (OS). Results: The median PFS time was 11.0 ± 0.3 and 14.1 ± 0.5 months in the Len and Ablation + Len groups, respectively. The PFS (hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.49-0.80, Conclusion: Ablation of PO combined with Lenvatinib resulted in longer PFS and OS than treatment with Lenvatinib alone. However, patients did not derive survival benefits from the ablation of metastases when the hepatic tumors were in SD status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.